Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Orr

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Opinion in Molecular Therapeutics|August 11, 2001
Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA visionR M Orr
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: electroporation therapy, Genetronics IncR M Orr
Idrugs : the Investigational Drugs Journal|August 19, 2005
Molecular targets and cancer therapeutics: discovery, development & clinical validation--AACR-NCI-EORTC international conferenceR M Orr
Current Opinion in Molecular Therapeutics|November 21, 2001
Technology evaluation: leukemia therapy, University of PennsylvaniaR M Orr
Current Opinion in Investigational Drugs (London, England : 2000)|March 14, 2002
GTI-2040. Lorus TherapeuticsR M Orr
Idrugs : the Investigational Drugs Journal|May 10, 2008
Antisense therapy for cancerR M Orr, B P Monia
Current Opinion in Molecular Therapeutics|March 16, 2001
Patent review: therapeutic applications for antisense oligonucleotides 1999-2000R M Orr, C F O'Neill
British Journal of Cancer|January 1, 1994
The role of apoptosis in cell killing by cisplatin: a flow cytometric studyM G Ormerod, R M Orr, J H Peacock
The Journal of Cardiovascular Surgery|September 1, 1990
Management of deep venous thrombosis in the pregnant femaleJ C Rosenfeld, F P Estrada, R M Orr
Neoplasma|January 1, 1992
The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatinM C Nicolson, R M Orr, C F O'Neill, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Opinion in Molecular Therapeutics|August 11, 2001
Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA visionR M Orr
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: electroporation therapy, Genetronics IncR M Orr
Idrugs : the Investigational Drugs Journal|August 19, 2005
Molecular targets and cancer therapeutics: discovery, development & clinical validation--AACR-NCI-EORTC international conferenceR M Orr
Current Opinion in Molecular Therapeutics|November 21, 2001
Technology evaluation: leukemia therapy, University of PennsylvaniaR M Orr
Current Opinion in Investigational Drugs (London, England : 2000)|March 14, 2002
GTI-2040. Lorus TherapeuticsR M Orr
Idrugs : the Investigational Drugs Journal|May 10, 2008
Antisense therapy for cancerR M Orr, B P Monia
Current Opinion in Molecular Therapeutics|March 16, 2001
Patent review: therapeutic applications for antisense oligonucleotides 1999-2000R M Orr, C F O'Neill
British Journal of Cancer|January 1, 1994
The role of apoptosis in cell killing by cisplatin: a flow cytometric studyM G Ormerod, R M Orr, J H Peacock
The Journal of Cardiovascular Surgery|September 1, 1990
Management of deep venous thrombosis in the pregnant femaleJ C Rosenfeld, F P Estrada, R M Orr
Neoplasma|January 1, 1992
The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatinM C Nicolson, R M Orr, C F O'Neill, et al.
Pageof 3